Abstract
Introduction The previously developed LIFEtime-perspective CardioVascular Disease (LIFE-CVD) model can be used to predict lifetime cardiovascular disease risk, CVD-free life expectancy, and lifetime benefit from cardiovascular risk factor treatment in apparently healthy people aged 45 to 80 years. However, there was an unmet need to be able to apply the model in patients younger than 45 years, and to accurately estimate treatment effects in patients with a life expectancy exceeding 90 years.
Aim Update the LIFE-CVD model to enable application of the model in people aged 35 to 89 years, and to allow more accurate estimation of treatment effects in patients with a life expectancy exceeding 90 years.
Methods The study was conducted using data from the same studies as were used for derivation and validation of the original model, including the Multi-Ethnic Study of Atherosclerosis (MESA) cohort, Atherosclerosis Risk in Communities Study (ARIC) cohort, and the European Prospective Investigation into Cancer-Netherlands (EPIC-NL) and EPIC-Norfolk cohort studies. Age-specific baseline survivals were smoothed by predicting the progression of baseline survivals with age, using a local polynomial regression function and a exponential function for CVD, and non-CVD mortality baseline survivals respectively. Using these functions, baseline survivals were then extrapolated to the age range of 35 to 100 years. External validation using the newly updated baseline survivals was performed.
Results Performance of the updated model was not dissimilar from the original model, with C-statistics for discrimination ranging from 0.70-0.76 in the external study populations. Calibration plots showed a good agreement between predicted and observed 10-year CVD risks. Estimation of treatment effects in patients with a life expectancy exceeding 90 years was improved.
Conclusion This update of the LIFE-CVD model improves the clinical usability of the model by increasing the age range and improving the method of estimation of lifetime treatment effects.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Authors did not receive funding for this work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Approval was given by IRBs/oversight bodies for the individual studies, of which data is used in this study.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data requests may be send to the corresponding author.